INmune Bio Inc
NASDAQ:INMB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (1 072.8), the stock would be worth $6.11 (340% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 244 | $1.39 |
0%
|
| 3-Year Average | 1 072.8 | $6.11 |
+340%
|
| 5-Year Average | 695.4 | $3.96 |
+185%
|
| Industry Average | 6.2 | $0.04 |
-97%
|
| Country Average | 3 | $0.02 |
-99%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
$7.9m
|
/ |
Jan 2026
$50k
|
= |
|
|
$7.9m
|
/ |
Dec 2027
$6.5m
|
= |
|
|
$7.9m
|
/ |
Dec 2028
$25.6m
|
= |
|
|
$7.9m
|
/ |
Dec 2029
$98.5m
|
= |
|
|
$7.9m
|
/ |
Dec 2030
$172m
|
= |
|
|
$7.9m
|
/ |
Dec 2031
$253.7m
|
= |
|
|
$7.9m
|
/ |
Dec 2032
$336.3m
|
= |
|
|
$7.9m
|
/ |
Dec 2033
$383.8m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
INmune Bio Inc
NASDAQ:INMB
|
37m USD | 244 | -0.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 6.6 | 83.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 6.1 | 23.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 5.8 | 18.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 8.4 | 27.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 4 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 10.7 | 37.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 3.5 | 31.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 3 |
| 70th Percentile | 5.3 |
| Max | 4 613 320.1 |
Other Multiples
INmune Bio Inc
Glance View
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2019-02-04. The firm is focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Its drug candidates include INKmune, INB03, and XPro1595 (XPro). The company has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor alpha (TNF), a driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is being developed for Alzheimer's and treatment-resistant depression (XPro) and cancer (INB03). The Natural Killer (NK) Cell Priming Platform includes INKmune for priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic malignancies, solid tumors, and chronic inflammation.
